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LETTERS TO THE EDITOR
Does Glucocorticoid Dysregulation
Contribute to the Link Between
Cigarette Smoking and Insulin Resistance?
In a recent issue of the Journal, Drs. Reaven and Tsao (1) discussed
the association between cigarette smoking and insulin resistance,
endothelial dysfunction, and dyslipidemia. They assert that insulin
resistance may be a key mechanism by which smoking increases the
risk of atherosclerotic cardiovascular disease. We agree with this
assertion and suggest that elevated glucocorticoid tone may be an
important link between cigarette smoking and insulin resistance.
Cigarette smokers may have higher serum cortisol levels than
nonsmokers of similar age and body mass index (BMI) (2).
Furthermore, elevated afternoon cortisol levels appear to fall after
smoking cessation (3). Although the mechanisms for altered
glucocorticoid homeostasis in smokers remains to be defined, it is
well known that long-term glucocorticoid exposure causes visceral
obesity and carbohydrate insulin resistance, and it is also likely that
interindividual variation in glucocorticoid homeostasis contributes
to insulin resistance in the general population (4). Thus, it is
plausible that chronically dysregulated glucocorticoid homeostasis
in smokers may have adverse effects on glucose metabolism and
body fat distribution.
Visceral obesity—even when BMI is normal or low—is asso-
ciated with insulin resistance and increased cardiovascular risk, and
cigarette smokers may have a two-fold greater risk of developing
this anthropometric phenotype compared with nonsmokers (5).
This observation provides further circumstantial evidence that
altered glucocorticoid homeostasis in smokers might have chronic
consequences. In summary, the link between smoking and insulin
resistance may be at least partly explained by elevated activity of the
stress hormone cortisol.
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We appreciate the support of Drs. Girod and Brotman for our
hypothesis that the increased prevalence of insulin resistance and
hyperinsulinemia in cigarette smokers may play a central role in the
dyslipidemia, endothelial dysfunction, and increased cardiovascular
disease associated with tobacco use. However, we are not as
persuaded as they seem to be that the link between cigarette
smoking and insulin resistance is mediated via higher serum
cortisol levels, secondary to smoking-induced visceral obesity. For
example, in our initial study (1) we documented the presence of
insulin resistance and compensatory hyperinsulinemia in smokers
as compared with nonsmokers, matched for age, gender, family
history of diabetes, alcohol consumption, level of physical
activity, body mass index (BMI), and the ratio of waist-to-hip
girth (WHR). Subsequent studies have also demonstrated that
insulin resistance/hyperinsulinemia can be demonstrated in
smokers independently of either BMI or WHR, and in two of
these studies (2,3) it was shown that the enhancement of insulin
sensitivity occurring with smoking cessation can be seen despite
weight gain.
Conversely, in none of these studies was body fat distribution
quantified by computerized tomography. Thus, the suggestion that
the insulin resistance of smokers is due to a redistribution of body
fat, with a relative increase in visceral obesity, cannot be dismissed.
However, it should be noted that the observation of a smoking-
related change in body fat distribution was made in only one ethnic
group (4), and individuals of Korean ancestry may not be charac-
teristic of the world at large. Furthermore, direct measurements of
visceral obesity were not performed, and the suggestion that
visceral obesity was present was based entirely on evidence that the
ratio of WHR/BMI was increased in smokers. It should also be
noted that the two-fold risk to have the highest WHR/BMI ratio
was limited to 4.7% and 3.8% of the male and female smokers,
respectively.
Finally, the relationship between visceral obesity and insulin
resistance is a complex one. Perhaps the most revealing example of
this is the recent report by Seppala-Lindroos et al. (5), showing
with proton spectroscopy and magnetic resonance imaging in
healthy volunteers that hepatic fat content was unrelated to
amount of visceral fat, whereas the amount of fat in the liver, not
visceral fat, was closely related to a variety of abnormalities
associated with insulin resistance, including fasting hyperinsulin-
emia. In contrast, the formulation advanced by Girod and Brot-
man is certainly testable, and despite our skepticism it is worthy of
experimental verification. Most importantly, the correspondents’
letter should serve, along with our original comments, to indicate
the need for a better understanding of the relationship between
cigarette smoking and the wide variety of metabolic factors with
which it is associated.
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Clopidogrel Versus Ticlopidine After
the Placement of Coronary Artery Stents
In a study published recently in JACC, Mueller et al. (1) compared
treatment with clopidogrel and aspirin to ticlopidine and aspirin in
patients undergoing coronary stent placement. Both drugs were
started after the procedure and continued for four weeks. Ticlo-
pidine was given as a 500-mg loading dose followed by 250 mg
twice daily thereafter; however, clopidogrel was given without
loading: 75 mg daily. The results suggested that clopidogrel was
inferior to ticlopidine in terms of cardiovascular mortality. In other
studies involving clopidogrel, a loading dose of 300 mg was given
initially followed by 75 mg daily thereafter (2,3). A loading dose of
300 mg of clopidogrel is needed in order to achieve timely platelet
inhibitory effect (4). The lack of clopidogrel loading clearly delays
the effect of clopidogrel and, therefore, may cause a higher
thrombotic stent occlusion (TSO) rate (the TSO rate was not
reported by Mueller et al.). Use of a clopidogrel loading dose in
this instance may show clopidogrel not to be inferior to ticlopidine
(3).
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We fully agree with Dr. Rott that the lack of a loading dose of
clopidogrel is an important issue in interpreting our data. After
completion of our study, two major clinical trials, Clopidogrel for
the Reduction of Events During Observation (CREDO) (1) and
ISAR-REACT (2), were reported that highlight the need for a
loading dose of clopidogrel. In CREDO, the best clinical outcome
was seen in those patients who achieved the full antiplatelet effect
of clopidogrel at the time of intervention, which was 6 h after a
loading dose of 300 mg. Based on clinical observations (3) and ex
vivo analysis of platelet function (4), the ISAR-REACT trial used
an even higher loading dose of clopidogrel, 600 mg, which enables
the full antiplatelet effect of clopidogrel within 2 h (4). With this
loading scheme, the antithrombotic efficacy in patients undergoing
elective interventions could not be further improved even with
abciximab, as shown by the composite 30-day end point of death,
myocardial infarction, and urgent revascularization (2).
In light of these new findings, we cannot exclude that the results
of our trial, as well as those of other trials suggesting inferiority of
clopidogrel compared with ticlopidine (5), would have been
different had an appropriate loading dose been used. Notably, a
high loading dose may overcome the other potential explanation of
our findings, which is the interference of statins. Although the
issue has not been completely settled, preliminary reports indicate
that attenuation of the antiplatelet effect by statins is not detectable
after a 600-mg loading dose (6).
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